Cubist Systematic Strategies, LLC Cue Biopharma, Inc. Transaction History

Cubist Systematic Strategies, LLC

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$1.24 - $2.18 $5,143 - $9,042	4,148 New	4,148 $5,000
Q1 2023 May 15, 2023	SELL	$2.41 - $3.74 $161 - $250	-67 Reduced 0.17%	40,320 $143,000
Q3 2022 Nov 14, 2022	SELL	$2.23 - $3.37 $48,560 - $73,385	-21,776 Reduced 35.03%	40,387 $90,000
Q2 2022 Aug 15, 2022	BUY	$2.49 - $5.92 $88,469 - $210,337	35,530 Added 133.41%	62,163 $155,000
Q1 2022 May 16, 2022	BUY	$4.41 - $12.28 $117,451 - $327,053	26,633 New	26,633 $130,000
Q4 2021 Feb 14, 2022	SELL	$10.86 - $17.85 $143,525 - $235,905	-13,216 Closed	0 $0
Q3 2021 Nov 15, 2021	SELL	$10.06 - $15.3 $129,955 - $197,645	-12,918 Reduced 49.43%	13,216 $193,000
Q2 2021 Aug 16, 2021	BUY	$10.9 - $14.53 $284,860 - $379,727	26,134 New	26,134 $304,000
Q1 2021 May 17, 2021	SELL	$11.2 - $16.09 $131,241 - $188,542	-11,718 Closed	0 $0
Q4 2020 Feb 16, 2021	BUY	$11.12 - $16.4 $130,304 - $192,175	11,718 New	11,718 $147,000
Q3 2020 Nov 16, 2020	SELL	$15.05 - $23.54 $326,931 - $511,359	-21,723 Closed	0 $0
Q2 2020 Aug 14, 2020	BUY	$12.7 - $30.73 $275,882 - $667,547	21,723 New	21,723 $532,000

14.1M

14.4K

2.6K

Ticker CUE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 35,381,700
Market Cap $38.2M
Description
Cue Biopharma, Inc., a clinical-stage biopharmaceutical company, develops biologic drugs for the selective modulation of the human immune system to treat a range of cancers, chronic infectious diseases, and autoimmune disorders. Its lead drug candidate is CUE-101, a fusion protein biologic that is in Phase 1b clinical trial designed to target an...

Get notified when there are updates to the investment portfolio of Cubist Systematic Strategies, LLC, based on Form 13F filings with the SEC.

Stay updated on Cubist Systematic Strategies, LLC with notifications on news.